Interactive Transcript
0:01
I'd like to talk about multiple sclerosis
0:04
and the criteria that are used in America
0:07
and in Europe for diagnosing
0:10
multiple sclerosis.
0:12
It's important to emphasize that multiple
0:14
sclerosis remains a clinical diagnosis
0:16
where MR is very strong paraclinical evidence.
0:20
It's true that MR is being used greater and
0:23
greater for the diagnosis of multiple sclerosis,
0:26
but it's always in concert with the clinical
0:29
manifestations of the disease.
0:31
This is a disease which has interesting
0:34
demographics, insofar as most of the patients
0:37
are between 20 and 50 years of age.
0:40
Although, you do see 15% of patients who have
0:44
an initial diagnosis of multiple sclerosis
0:46
made after 50 years of age
0:48
and 13% under 20 years of age.
0:53
It is a diagnosis
0:55
which has some genetic predilection.
0:57
As you see,
0:58
siblings have a higher rate,
1:00
as well as children have a higher rate of multiple
1:04
sclerosis with their siblings or parents.
1:07
It also has some temperate regions,
1:10
in that the temperate climates have a higher rate
1:14
of multiple sclerosis than those at the
1:16
extremes of temperature.
1:17
And part of this has been suggested
1:21
may be related to vitamin D deficiency,
1:24
which is what some people have suggested
1:29
may show a predilection for development
1:32
of multiple sclerosis.
1:34
However, most people believe that this is an
1:36
autoimmune inflammatory condition,
1:39
as likely to have been precipitated by some viral etiology.
1:44
As we saw on the imaging,
1:46
the classic sites for multiple sclerosis
1:49
are in the periventricular location,
1:51
juxtacortical location,
1:53
brain stem and optic nerve.
1:56
In the course of a patient's life
1:59
who has multiple sclerosis,
2:02
80% of them,
2:03
80% of them have an episode of
2:06
optic neuritis where the optic
2:08
nerve is affected.
2:09
Gray matter disease,
2:11
we are now recognizing
2:12
more readily because of high-resolution imaging,
2:15
as well as high-field strength imaging.
2:17
Although, this slide says 5% in the gray matter,
2:20
that's probably now felt to
2:23
represent more like 15%.
2:25
And there's a broad differential diagnosis
2:28
that is included when one has multiple
2:30
white matter lesions in the brain.
2:32
Most commonly,
2:33
we think of the diagnoses of acute
2:36
disseminated encephalomyelitis,
2:38
Lyme disease, vasculitis, sarcoidosis,
2:41
lupus, SAE, and toxins,
2:44
as well as migraines, SAE, in other words,
2:47
Binswanger's disease.
2:49
And that's a little bit of an older age group.
2:52
So the McDonald criteria initially said that
2:55
you had to have three out of four
2:58
of the following on MRI.
3:00
Those are a gad-enhancing lesion or nine
3:02
hyperintense lesions, infratentorial,
3:04
juxtacortical,
3:05
and three or more periventricular lesions
3:08
and/or gadolinium enhancement that was greater
3:11
than three months after a
3:12
non-enhancing lesion.
3:14
These McDonald criteria were revised and the
3:17
new McDowell criteria,
3:18
which we're working under currently,
3:20
which were developed in 2011,
3:23
or approved in 2011,
3:25
define dissemination in space
3:28
as at least one T2 lesion,
3:32
in at least two of the four areas
3:35
that we've described previously,
3:37
the periventricular region,
3:38
the juxtacortical region,
3:40
infratentorial, portion of the brain,
3:43
and the spinal cord.
3:45
Dissemination in time is defined by
3:49
appearance of a new lesion on a second scan
3:51
and may not necessarily be enhancing,
3:54
or simultaneous presence of an asymptomatic
3:58
gadolinium-enhancing and non-enhancing
4:00
lesion on a single scan.
4:02
Now, I have to say that one of the caveats
4:05
or one of the confusing aspects of the McDonald
4:09
criteria is this statement
4:11
about asymptomatic,
4:13
which obviously is difficult to identify a
4:17
specific clinical symptom for a small
4:20
white matter lesion, for example,
4:21
in the parietal white matter
4:23
or frontal white matter.
4:24
So this gets some criticism,
4:26
the inclusion of this word asymptomatic.
4:29
These are the McDonald criteria that most
4:31
programs in the United States follow.
4:34
However,
4:35
in Europe, they follow a different consensus,
4:39
and this is a more recent one in 2016.
4:42
This is the MAGNIMS
4:44
or Magnetic Resonance Imaging
4:47
in Multiple Sclerosis consensus,
4:49
and they will utilize the McDonald criteria
4:54
with the following caveats.
4:55
They include optic neuritis as a separate
4:59
location for the definition of multiple
5:03
sclerosis dissemination space.
5:04
You still need two or more.
5:06
But in addition to periventricular
5:09
juxtacortical,
5:11
infratentorial and spinal cord,
5:14
they also include optic neuritis
5:16
as a fifth location.
5:18
They reclaim having greater than
5:23
three periventricular lesions.
5:25
So a single periventricular lesion,
5:28
which is appropriate for the McDonald
5:30
criteria in America,
5:32
is insufficient in the MAGNIMS consensus,
5:36
they require three or more
5:39
periventricular lesions.
5:40
They also add the cortical lesion
5:43
to the juxtacortical lesion,
5:46
which is not mentioned in
5:48
the McDonald criteria,
5:50
and they correct that issue with regard to
5:54
an asymptomatic plaque
5:55
in the dissemination time.
5:57
It need not be asymptomatic.
5:59
As long as there's a new lesion
6:00
or enhancing and non-enhancing
6:03
lesions on the same study,
6:05
you fulfill the dissemination in time
6:07
criteria for multiple sclerosis
6:10
using the MAGNIMS consensus.
6:12
And frankly,
6:13
I like this a lot better.
© 2024 Medality. All Rights Reserved.